Greg Kunst

Company: Aurion Biotech

Job title: President, Chief Executive Officer & Board Member

Seminars:

Focusing in on the Regulatory Landscape for Allogeneic Cell Therapies 3:30 pm

Examining acceptance criteria expectations around gene editing, toxicity, and potency assays Highlighting importance of early CMC work to enable efficient manufacturing scale-up for allogeneic products Evaluating opportunities to align global regulatory perspectives on allogeneic therapiesRead more

day: Day Two